Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Small G protein signaling modulator 1 (SGSM1) is a cytosolic and cytoplasmic vesicle-associated protein primarily expressed in the central nervous system, containing RUN and TBC1 domains[1][2][7]. SGSM1 functions as a modulator of small GTPase signaling, acting as both an effector and GTPase activator for various members of the Rab and Rap family of small G proteins, particularly promoting GTP hydrolysis by RAB34 and RAB36, but not RAB9A and RAB9B[1][7][2]. It is involved in intracellular signal transduction and vesicular trafficking, and influences pathways such as positive regulation of transcription by RNA polymerase II[1][2]. Mutations or genetic variation in SGSM1 have been associated with certain neurodegenerative disorders, but it is not currently established as a direct therapeutic target[1]. The canonical gene and protein name, as defined in gene/protein databases, is "Small G protein signaling modulator 1," with SGSM1 as its widely accepted abbreviation[1][2][4]. The primary molecular features are the RUN and TBC1 domains, placing it in the broad "Other" molecular classification; these domains relate to small GTPase regulatory mechanisms, but SGSM1 is not an enzyme, traditional receptor, transporter, or channel[2][7][10]. SGSM1 is a cytosolic protein involved in vesicle transport through Rab and Rap GTPase pathways, contributing to membrane trafficking necessary for neuronal and other cellular functions[1][2][7]. There is no evidence in the provided data or current research databases of direct drug interactions, biomarker status, therapeutic mechanism, or safety issues—nor is it currently a typical small-molecule drug target[1][2][4]. Genetic mutations in SGSM1 have been associated with rare inherited neurological disorders such as autosomal dominant adult-onset proximal spinal muscular atrophy and autosomal recessive spastic paraplegia 57[1]. Aliases are consistent across major genomic and protein resources and include all names listed in the query[1][2][4]. No evidence of misspelling, incorrectness, or inappropriateness as a protein/gene target (SGSM1 is a valid, well-characterized protein-coding gene)[1][2][4][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Small G protein signaling modulator 1 (SGSM1).